Form 4: Nuvalent Director Anna Protopapas Reports Acquisition of Shares and Stock Options

Director Anna Protopapas reports acquisition of Nuvalent, Inc. Class A Common Stock and stock options.

Summary

• On June 12, 2024, Anna Protopapas, a director of Nuvalent, Inc., reported the acquisition of 2,499 shares of Class A Common Stock under restricted stock units (RSUs) at a price of $0.00 per share.
• These RSUs vest in full on the earlier of June 12, 2025, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, contingent upon continued service to the company.
• Protopapas also acquired stock options for 3,789 shares of Class A Common Stock with an exercise price of $80.03.
• These options vest in full on the earlier of June 12, 2025, or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service, and expire on June 12, 2034.
• Following these transactions, Protopapas directly owns 2,499 shares of Class A Common Stock and holds options for 3,789 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director is generally a good sign, indicating confidence in the company's prospects. However, it's a routine filing and doesn't provide significant new information.

Positives

• The acquisition of shares and stock options by a director signals confidence in the company's future prospects.
• The vesting schedules tied to continued service align the director's interests with the long-term success of Nuvalent, Inc.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules suggest a commitment to the company's future.

Industry Context

This filing is a routine disclosure related to insider transactions, common in the biopharmaceutical industry where equity compensation is frequently used.

Comparison to Industry Standards

• Equity grants to directors are a common practice in the biotechnology industry to align their interests with shareholders.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also use stock options and RSUs as part of their director compensation packages.
• The vesting schedules and exercise prices are generally in line with industry standards for similar-stage companies.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it reflects a director's investment in the company.
• Employees may view this as a positive sign of leadership's commitment.

Key Dates